Cetuximab in metastatic colorectal cancer
作者： Vy Tuong Broadbridge , Cristos S Karapetis , Timothy Jay Price
DOI: 10.1586/ERA.12.25
关键词:
摘要: Management of metastatic colorectal cancer has evolved in the last 10 years, with availability targeted therapies resulting improvement quality life and overall survival. Cetuximab is a chimeric monoclonal antibody that binds to EGF receptor, net effects are inhibition tumor growth, invasion, angiogenesis metastasis. binding receptor also known augment chemotherapy radiotherapy. Only tumors expressing wild-type KRAS respond cetuximab improvements progression-free survival seen, whereas patients mutant considered be resistant. currently available worldwide for use as monotherapy or combination first-, second- third-line settings KRAS.
core.ac.uk
expert-reviews.com参考文章(70)
J. Metges, J. Raoul, N. Achour, O. Capitain, A. Gourlaouen, J. Ramée, J. Egreteau, J. Douillard, S. Traoré, F. Grudé, PANERB study: Panitumumab after cetuximab-based regimen failure. Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.E14000
S. Stintzing, J. Neumann, A. Jung, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jaeger, T. Heintges, C. Stoll, D. P. Modest, T. Kirchner, W. Scheithauer, V. Heinemann, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. Journal of Clinical Oncology. ,vol. 29, pp. 3575- 3575 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.3575
Heinz-Josef Lenz, Cetuximab in the management of colorectal cancer Biologics: Targets & Therapy. ,vol. 1, pp. 77- 91 ,(2007)
Christina Wu, Aline Charabaty, Michael Pishvaian, John L. Marshall, Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Current Colorectal Cancer Reports. ,vol. 4, pp. 15- 21 ,(2010) , 10.1007/S11888-010-0061-2
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
Aminah Jatoi, Kendrith Rowland, Jeff A. Sloan, Howard M. Gross, Paul A. Fishkin, Stephen P. Kahanic, Paul J. Novotny, Paul L. Schaefer, David B. Johnson, Loren K. Tschetter, Charles L. Loprinzi, Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer. ,vol. 113, pp. 847- 853 ,(2008) , 10.1002/CNCR.23621
C Meads, J Round, S Tubeuf, D Moore, M Pennant, S Bayliss, Cetuximab for the first-line treatment of metastatic colorectal cancer Health Technology Assessment. ,vol. 14, pp. 1- 8 ,(2010) , 10.3310/HTA14SUPPL1/01
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
D Balin-Gauthier, J-P Delord, M-J Pillaire, P Rochaix, J-S Hoffman, R Bugat, C Cazaux, P Canal, B C Allal, Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation British Journal of Cancer. ,vol. 98, pp. 120- 128 ,(2008) , 10.1038/SJ.BJC.6604134